MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim...
<jats:title>Abstract</jats:title> <jats:p>Resistance to doxorubicin (DOX) is the most common clinical problem in breast cancer therapy, and the underlying molecular mechanism remains to be investigated. MicroRNAs (miRNAs) exhibit important regulatory functions in var...
|Journal Title:||Bioscience Reports|
|Authors and Corporations:||, , , ,|
|In:||Bioscience Reports, 39, 2019, 7|
|Type of Resource:||E-Article|
Portland Press Ltd.